This episode of the EMJ podcast delves into treatment options for patients with intermediate-risk (IR) non-muscle invasive bladder cancer (NMIBC). With a wide range of subgroups that patients with IR NMIBC can fit into, there are many challenges associated with selecting optimal treatment options. Rodolfo Hurle, Chief of the Bladder Unit at IRCCS Humanitas Research Hospital, Milan, Italy, offers his expert perspective on this pertinent topic, as well as insights into the current standard-of-care for patients with IR NMIBC.
Highlighting the risk factors that need to be taken into consideration during the substratification of patients with IR NMIBC, Hurle explains the different approaches to treatment, as well as the duration of maintenance instillations. The potential roles of chemohyperthermia and neoadjuvant therapy for patients with IR NMIBC are explored, with Hurle providing key takeaway insights to listeners.